The business programme architecture of the ‘Ensuring Drug Security’ Russian Pharmaceutical Forum has been published on the event’s official website. The Forum will take place on 5 June 2024, the opening day of the St. Petersburg International Economic Forum (SPIEF).

The Forum is being organized by the Roscongress Foundation and the Russian Ministry of Health with the support of the Subcommittee on the Circulation of Medicines and the Development of the Pharmaceutical and Medical Industry of the Russian State Duma’s Committee on Health Protection. The Forum, which is held annually and is attended by representatives of foreign countries, is the leading platform for discussions about technological sovereignty in the pharmaceutical industry.

“The Drug Security Forum is the annual flagship event of the pharmaceutical industry. For the fourth year in a row, on the opening day of the St. Petersburg International Economic Forum, leading representatives of the industry, government bodies, and public organizations will get together. The Forum is being held with the participation of the international expert community. We are intensifying cooperation with friendly countries and are open to the exchange of experience and the implementation of joint projects that aim to strengthen drug security in our countries,” said Alexander Petrov, a State Duma deputy and chair of the Expert Council on the Circulation of Medicines and the Development of the Pharmaceutical and Medical Industry of the Committee on Health Protection.

As part of Russia’s current BRICS chairship, a substantial part of the event’s business programme will focus on issues related to the development of long-term fruitful cooperation between BRICS countries in healthcare, the development of high technologies, and the pharmaceutical industry. The Forum’s plenary session is titled ‘Drug Security in the BRICS Space’.

The key discussion topics at the Forum are: Pharma 2030 and the long-term planning course; new approaches to the circulation of medicines; rare diseases and innovative approaches to therapy, patient care, and the establishment of domestic orphan drug production; the future of the diagnosis and treatment of autoimmune diseases; biomedical technologies as the cornerstone of technological sovereignty; pharmacy chains and distribution: strategies for successful partnerships; food as medicine; how domestic pharmaceutical products win over consumer trust; and more.